Clinical Trial Wound Care Success: 7 Questions to Ask

The management of chronic, non-healing wounds remains one of the most persistent and costly challenges in modern healthcare. These complex conditions—ranging from diabetic foot ulcers to venous stasis wounds—not only drastically reduce patient quality of life, but also place a significant burden on health systems. In fact, one 54-center health system in Spain spent an estimated $39 million on chronic wound care over a two-year period.

As frontline practitioners, wound care specialists understand that simply following existing protocols is not enough. Continuous innovation is an important practice to improve healthcare and enable better patient outcomes. For large clinics and health systems, this means moving beyond the role of passive treatment providers and becoming active partners in advancing the field. Such evolution requires embracing a dynamic ecosystem built on three pillars of progress:

• Aggressive research and development (R&D) to discover new modalities
• Validation of new treatments through rigorous clinical trials
• Swift, evidence-based integration of next-generation technology

Here we examine the clinical innovation pipeline, highlighting the latest advances in research and technology and providing specialists with the essential questions and actionable insights needed to confidently engage with the clinical trial process.

The State of R&D in Wound Care

The field of wound care is undergoing a fundamental shift, moving from a passive, reactive approach to an active, technology-driven model. This change is pushed forward by the urgent economic necessity of chronic wound management, which represents a substantial financial burden on health systems, as noted above.

Robust investment in R&D is essential to discover faster, more effective healing modalities; however, this R&D effort is complicated by the inherent complexity and heterogeneity (large variability due to placement, cause, etc.) of chronic wounds. The wide variety of patient comorbidities and inconsistent wound environments can create a frequent  research gap that challenges traditional, standardized research methods and clinical trial enrollment.

Understanding the R&D Journey

The journey of clinical innovation, known as translational science, moves a concept from the bench to the bedside; that is to say, this process moves ideas from theoretical stage to the clinical trial to directly benefit patients.  It ensures that new products are safe, effective, and evidence-backed.

The process begins with idea generation based on unmet clinical needs, followed by rigorous preclinical testing to demonstrate initial safety. This testing includes in vitro (in a lab setting) studies of a material’s biocompatibility and in vivo (in living organisms) studies to simulate  healing.

Modern R&D in Wound Care

Today’s wound care R&D is focused on solving the core challenges of chronic wounds, such as persistent inflammation and biofilm management.

• Personalized cellular therapies: Using bio-print technology and engineered scaffolds to actively support tissue regeneration.
• Targeted drug delivery: Developing specialized systems like hydrogels that  deliver antimicrobial agents or growth factors directly to the wound bed.
• Advanced diagnostics: Creating point-of-care tools for objective, real-time assessment of infection, tissue viability, and healing trajectory.

Notably, successful R&D requires a multi-disciplinary approach. It relies on a collaborative loop involving material scientists, biologists, data experts, and, most importantly, wound care clinicians whose insights drive the next generation of patient solutions.

Decoding the Landscape of New Wound Care Technology

As a wound care practitioner, you’ve no doubt faced a rapid influx of new products in the last few years. Deciphering the actual value of next-generation technology requires understanding the core science and clinical data that drives that technology instead of just believing the marketing hype.

With that said, this new landscape of wound care innovation can be broken down into two main categories: advanced materials and digital solutions.

Next-Generation Treatments

The evolution of physical treatment modalities focuses on actively supporting the healing cascade.

• Biologic skin substitutes and grafts: These products, derived from human or animal tissue, provide a scaffold of  viable cells to replace or assist with  lost skin function. They are critical interventions for deep, complex, or chronic wounds that have stalled in the healing process.
• Advanced dressing materials: Modern dressings are dynamic and do more than just provide a barrier. Innovations include hydrogels that provide hydration for dry wounds, antimicrobial foams infused with agents like silver to manage bioburden, and hydrofibers that transform into a gel to manage high exudate while maintaining a moist environment.
• Energy-based therapies: Established modalities like negative pressure wound therapy (NPWT) have become more portable and convenient, increasing patient mobility. Emerging therapies are also gaining traction, such as non-thermal plasma (NTP) or focused ultrasound, which utilize targeted energy delivery to sterilize the wound bed and  stimulate cellular activity.

The Rise of Digital Wound Care

Digital tools are standardizing assessment and dramatically expanding access to specialized care. These tools include:

• Remote monitoring and telemedicine. Using smartphone photography and digital platforms, clinicians can conduct remote assessments, coordinate care, and track progress without requiring frequent in-person visits. This improves continuity of care, especially for patients in rural or home-health settings.
• Artificial intelligence (AI) and machine learning (ML). AI-driven digital wound care solutions are proving superior to current subjective practices. Algorithms can automatically measure wound size and area, predict healing trajectories with high accuracy, and assist in the early diagnosis of complications.

Clinical Trials in Wound Care: Evidence Engines for Evolution

The adoption of any new wound care product, whether an antimicrobial dressing or an AI-driven diagnostic tool, must be validated by high-quality clinical evidence. Clinical trials serve as the foundation for this evidence, ensuring that new treatments are not only safe but also measurably better than the existing standard of care.

Randomized Controlled Trials: The Gold Standard

The randomized controlled trial (RCT) is considered the gold standard in clinical research. The power of the RCT lies in its design: patients are randomly assigned to either the intervention group (receiving the new treatment) or the control group (receiving standard care or a placebo).

Randomization is critical for minimizing bias and ensuring that any observed difference in healing outcomes can be attributed to the new intervention itself. Given the significant heterogeneity of chronic wound patients, RCTs are essential for establishing true effectiveness and causality  across a diverse population.

Challenges Specific to Wound Care Trials

While RCTs are necessary, wound care trials face unique obstacles that require specialized protocols, like:

• Patient enrollment and retention. It is challenging to recruit patients with specific, non-uniform chronic wound types (e.g., deep venous ulcers vs. specific pressure injuries) who meet narrow eligibility criteria. Furthermore, the length of time required for complete healing leads to high dropout rates, making patient retention a persistent difficulty.
• Standardization of endpoints. Defining and consistently measuring “wound healing” is complex. While complete re-epithelialization is the ultimate goal, interim endpoints must be objective. These include consistent, measurable changes like the percentage of wound area reduction, which should  be tracked across multiple sites using standardized, objective methods to ensure data integrity.
• Ethical considerations. Trials must balance the ethical obligation to provide patients with the best available care with the requirements of a controlled study. This can be  particularly difficult when a control group is asked to forgo a treatment that is already considered a gold-standard approach, necessitating careful trial design and informed consent.

The Role of Regulatory Guidance and Health Systems

FDA guidance plays a key role, establishing specific requirements for proving both the safety and clinical benefit of wound care devices and biologics. These rigorous standards ensure that only truly beneficial products reach the market. Meanwhile, large, high-volume clinics and health systems you may be employed by or contracted with are uniquely positioned to serve as clinical trial investigators. Their access to a diverse and high volume of patients enables them to meet recruitment targets that smaller sites cannot.

Partners for Success: 7 Key Questions for Clinical Trial Engagement

For large clinics and health systems, acting as an investigative site for wound care clinical trials is a crucial opportunity to shape the future of medicine. However, trial participation is resource intensive and requires thorough due diligence to protect patient safety, organizational reputation, and financial stability.

Before signing any agreement with a sponsor or contract research organization (CRO), every system must be prepared to ask several key questions.

1. What Is the Primary Objective, Design, and Scientific Rigor of the Study?

You must ensure the research question is clinically relevant to your patient population and that the methodology is sound. Review the protocol to confirm the endpoints, control group selection, and whether or not blinding methods are rigorous enough to produce publishable, impactful results that will genuinely contribute to evidence-based practice.

2. What Are the Regulatory and Compliance Requirements for Our Staff and Facility?

Compliance is non-negotiable. Clarify all necessary certifications—especially training in Good Clinical Practice (GCP), the international standard for ethical and scientific quality—required for your staff. You must establish strict data security and privacy protocols (including HIPAA compliance) to protect patient data and your institution’s integrity.

3. What Is the Patient Recruitment Strategy and How Will It Impact Our Clinic’s Workflow?

Recruitment is the greatest hurdle for clinical trials in wound care. Specifically, “among the key challenges in chronic wound research is the timely completion of clinical trials that often experience slow or insufficient enrollment,” notes a systematic review of patient recruitment for chronic wound RCTs.

That’s why it’s important to assess the feasibility of meeting enrollment goals based on your patient volume. Further, you must understand the mechanisms the partner will provide to assist, such as pre-screening tools or dedicated study coordinators, to minimize disruption to your routine patient care workflow. A poorly managed trial can overwhelm your staff and diminish clinical quality.

4. What Are the Financial and Resource Commitments, and What Support Will the Partner Provide?

Research must be financially feasible . A detailed review of reimbursement schedules is essential to address staff time and procedures not covered by standard insurance. Ensure the agreement details the provision of all study materials, dedicated clinical research associate (CRA) support, and clear protocols for insurance coverage for participants in case of adverse events.

5. What Is the Plan for Data Management, Intellectual Property, and Dissemination of Results?

Establish clear guidelines on data ownership and your institutional investigators’ publication rights. Furthermore, demand transparency regarding trial outcomes, whether positive or negative, to fulfill your ethical obligation to contribute to the greater body of medical knowledge.

6. Can Our Clinical Trial Partner Ensure We Meet Regulatory and Compliance Guidelines?

While final responsibility for compliance rests with the investigative site, a reliable partner (sponsor or CRO) must demonstrate a robust plan to actively support your compliance efforts. This includes providing up-to-date standard operating procedures (SOPs), conducting thorough, scheduled monitoring and auditing of your data and site processes, and ensuring proper institutional review board (IRB) communication to maintain the ethical and legal integrity of the study.

7. What Will Our Clinical Partner Do to Keep Patients Engaged in the Trial?

Chronic wound clinical trials are long and demanding, leading to high dropout rates. More specifically, trials often face challenges such as the:

• Inability for patients to tolerate the intervention
• Lack of efficacy for the intervention
• Difficulty or inability for patients to attend clinical appointments and complete medical evaluations

Thus, following the patient recruitment strategy, your clinical partner should present a comprehensive patient engagement and retention plan.

This plan should detail strategies for minimizing the burden on patients, such as offering travel reimbursement, providing ongoing communication and support materials, and ensuring that all patient-facing study staff are well-trained in empathetic care to sustain motivation throughout the healing process.

Developing the Future of Evidence-Based Wound Care

The complexity and staggering financial burden of chronic wounds demand that health systems and wound care practitioners continually dedicate themselves to discovering the best ways to treat patients, especially when conventional treatments fall short.

For large clinics and health systems, this often means engaging in clinical trials. For wound care specialists, it means safeguarding the clinical integrity of such research efforts while ensuring the well-being of patients.

Should your organization embrace the role of an investigative site, you both will directly contribute to the evidence base, shape future treatment guidelines, and lead the inclusion  of proven, cost-effective modalities.